These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9722292)

  • 1. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts.
    Foot AB; Pamphilon D; Caul EO; Roome AP; Hunt LP; Cornish JM; Oakhill A
    Br J Haematol; 1998 Aug; 102(3):671-7. PubMed ID: 9722292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
    Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
    Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMV antigenemia following bone marrow transplantation: risk factors and outcomes.
    Osarogiagbon RU; Defor TE; Weisdorf MA; Erice A; Weisdorf DJ
    Biol Blood Marrow Transplant; 2000; 6(3):280-8. PubMed ID: 10871153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
    Lisini D; Zecca M; Giorgiani G; Montagna D; Cristantielli R; Labirio M; Grignani P; Previderè C; Di Cesare-Merlone A; Amendola G; Bergami E; Mastronuzzi A; Maccario R; Locatelli F
    Haematologica; 2008 Dec; 93(12):1859-67. PubMed ID: 18945748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
    Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic graft-versus-host disease in children and adolescents after bone marrow transplantation from HLA-matched donors.
    Yumura-Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Nakano T; Nomura K; Nakano T; Park DY; Endo C; Nishiuchi R; Sawada A; Matsuda Y; Oota H; Yoshimoto T; Kawa-Ha K
    Int J Hematol; 2000 Apr; 71(3):278-82. PubMed ID: 10846836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
    Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
    Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients.
    Yi ES; Kim YJ
    Yonsei Med J; 2012 Mar; 53(2):393-400. PubMed ID: 22318829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of unrelated-donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study.
    Bradley BA; Hows JM; Gore SM; Bidwell JL; Clay T; Downie TR; Gluckman E; Howard MR; Laundy GJ
    Clin Transpl; 1992; ():91-107. PubMed ID: 1306726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
    Tsinontides AC; Bechtel TP
    Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
    Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
    Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
    Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
    Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
    Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
    Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haploidentical related transplants and unrelated donor transplants with T cell addback.
    Veys PA; Meral A; Hassan A; Goulden N; Webb D; Davies G
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S42-4. PubMed ID: 9630324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants.
    Humar A; Wood S; Lipton J; Messner H; Meharchand J; McGeer A; MacDonald K; Mazzulli T
    Clin Infect Dis; 1998 Mar; 26(3):606-10. PubMed ID: 9524831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
    Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.